Last quarter (Q4 2022), Hikma Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Hikma Pharmaceuticals's net income was $―. See Hikma Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	$ 2.52B	$ 2.55B	$ 2.34B	$ 2.21B	$ 2.07B
Cost of Revenue	-	$ 1.28B	$ 1.25B	$ 1.14B	$ 1.12B	$ 1.02B
Gross Profit	-	$ 1.24B	$ 1.30B	$ 1.20B	$ 1.09B	$ 1.05B
Operating Expense	-	$ 755.00M	$ 704.00M	$ 641.00M	$ 639.00M	$ 679.00M
Operating Income	-	$ 483.00M	$ 597.00M	$ 560.00M	$ 449.00M	$ 371.00M
Net Non Operating Interest Income Expense	-	$ -45.00M	$ 39.00M	$ -22.00M	$ -1.00M	$ -77.00M
Other Income Expense	-	$ 11.00M	-	-	-	-
Pretax Income	-	$ 233.00M	$ 544.00M	$ 558.00M	$ 491.00M	$ 293.00M
Tax Provision	-	$ 42.00M	$ 124.00M	$ 128.00M	$ 4.00M	$ 8.00M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	$ 188.00M	$ 421.00M	$ 431.00M	$ 486.00M	$ 282.00M
Basic EPS	-	$ 0.84	$ 1.82	$ 1.83	$ 2.01	$ 1.17
Diluted EPS	-	$ 0.84	$ 1.81	$ 1.81	$ 2.00	$ 1.17
Basic Average Shares	-	$ 224.00M	$ 231.00M	$ 236.00M	$ 242.00M	$ 241.00M
Diluted Average Shares	-	$ 225.00M	$ 233.00M	$ 238.00M	$ 243.00M	$ 242.00M
Dividend Per Share	-	$ 0.37	$ 0.52	$ 0.46	$ 0.43	$ 0.35
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	$ 1.73	$ 1.50	$ 1.38
Reported Normalized Diluted E P S	-	-	-	$ 1.71	$ 1.50	$ 1.37
Rent Expense Supplemental	-	-	-	-	-	$ 13.00M
Total Expenses	-	$ 2.03B	$ -1.96B	$ 1.78B	$ 1.76B	$ 1.70B
Net Income From Continuing And Discontinued Operation	-	$ 188.00M	$ 421.00M	$ 431.00M	$ 486.00M	$ 282.00M
Normalized Income	-	$ 369.73M	$ 419.64M	$ 392.45M	$ 440.37M	$ 278.11M
Interest Expense	-	-	-	$ 56.00M	$ 51.00M	$ 41.00M
EBIT	-	$ 307.00M	$ 600.00M	$ 614.00M	$ 542.00M	$ 334.00M
EBITDA	-	$ 307.00M	$ 600.00M	$ 705.00M	$ 641.00M	$ 455.00M

Currency in USD

Hikma Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing